Metamizole Kalceks (Metamizole Sodium Monohydrate)

Metamizole inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis. This action decreases peripheral pain signaling and central sensitization, while also acting on hypothalamic pathways to lower body temperature.

The appropriate dose of Metamizole Kalceks is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and clinical response. Dosing regimens are individualized and should follow local prescribing guidelines.

Safety of Metamizole during pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under strict medical supervision.

To order, submit an enquiry on the Metamizole Kalceks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Metamizole offers non‑opioid analgesia with both pain‑relieving and antipyretic effects, distinguishing it from typical NSAIDs that may have stronger anti‑inflammatory activity. It is often chosen when rapid pain control is needed and when other analgesics are contraindicated, but it requires monitoring for rare blood‑related adverse events.

Metamizole Kalceks must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution before use.

Metamizole Kalceks is supplied as an injectable solution for intramuscular or intravenous administration. The route and rate of injection are selected by the healthcare professional according to the clinical situation.

The most serious risks include agranulocytosis, a potentially fatal drop in white‑blood‑cell count, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Immediate medical attention is required if signs of infection, rash, or breathing difficulty develop.

Metamizole is contraindicated in patients with known hypersensitivity to pyrazolones, existing agranulocytosis, severe hepatic or renal impairment, and in individuals with uncontrolled cardiovascular disease unless benefits outweigh risks.